Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer

F. Boccardo, M. Pace, A. Rubagotti, D. Guarneri, A. Decensi, F. Oneto, G. Martorana, L. Giuliani, F. Selvaggi, M. Battaglia, U. Delli Ponti, S. Petracco, P. Cortellini, M. Ziveri, V. Ferraris, G. P. Bruttini, R. Epis, G. Comeri, G. Gallo

Research output: Contribution to journalArticlepeer-review

Abstract

From March 1987 to December 1990, 373 patients with stage C and D prostate cancer were randomized to receive either goserelin acetate alone or goserelin acetate plus flutamide. At a median follow-up time of 24 months, there was no significant difference in the response rate, progression-free and overall survival between the two treatment groups. In particular, median time to progression was 18 months in the goserelin arm and 24 months in the combined treatment arm (P = 0.09). However, median time to progression in stage D patients was 12 months in both treatment groups. Median time to death was 32 and 34 months, respectively. The combination regimen produced a more rapid normalisation of prostatic acid phosphatase levels and a more prompt relief of bone pain. However, significantly more patients in the combination arm experienced treatment-related side-effects such as diarrhoea and increases in transaminase levels. The concurrent use of goserelin acetate and flutamide does not seem to significantly improve the results that can be achieved with goserelin acetate alone.

Original languageEnglish
Pages (from-to)1088-1093
Number of pages6
JournalEuropean Journal of Cancer
Volume29
Issue number8
DOIs
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer'. Together they form a unique fingerprint.

Cite this